JPWO2021037221A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021037221A5 JPWO2021037221A5 JP2022513162A JP2022513162A JPWO2021037221A5 JP WO2021037221 A5 JPWO2021037221 A5 JP WO2021037221A5 JP 2022513162 A JP2022513162 A JP 2022513162A JP 2022513162 A JP2022513162 A JP 2022513162A JP WO2021037221 A5 JPWO2021037221 A5 JP WO2021037221A5
- Authority
- JP
- Japan
- Prior art keywords
- cmsd
- modified
- receptor
- cell
- itam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 93
- 108020003175 receptors Proteins 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 34
- 108091008874 T cell receptors Proteins 0.000 claims description 32
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 101710192141 Protein Nef Proteins 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 16
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 10
- 208000024908 graft versus host disease Diseases 0.000 claims description 10
- 108020001756 ligand binding domains Proteins 0.000 claims description 10
- 230000000139 costimulatory effect Effects 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 101000995138 Homo sapiens NFAT activation molecule 1 Proteins 0.000 claims description 8
- 102100034394 NFAT activation molecule 1 Human genes 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 108700010039 chimeric receptor Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 4
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 4
- 102100027869 Moesin Human genes 0.000 claims description 4
- 102100025245 Signal transducing adapter molecule 1 Human genes 0.000 claims description 4
- 101710191634 Signal transducing adapter molecule 1 Proteins 0.000 claims description 4
- 102100025265 Signal transducing adapter molecule 2 Human genes 0.000 claims description 4
- 101710191637 Signal transducing adapter molecule 2 Proteins 0.000 claims description 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 108010071525 moesin Proteins 0.000 claims description 4
- 210000004986 primary T-cell Anatomy 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/103041 | 2019-08-28 | ||
| CN2019103041 | 2019-08-28 | ||
| CNPCT/CN2019/125681 | 2019-12-16 | ||
| CN2019125681 | 2019-12-16 | ||
| PCT/CN2020/112181 WO2021037221A1 (en) | 2019-08-28 | 2020-08-28 | Nef-containing t cells and methods of producing thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545815A JP2022545815A (ja) | 2022-10-31 |
| JPWO2021037221A5 true JPWO2021037221A5 (https=) | 2023-10-06 |
| JP2022545815A5 JP2022545815A5 (https=) | 2023-10-06 |
Family
ID=74683378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513162A Pending JP2022545815A (ja) | 2019-08-28 | 2020-08-28 | Ｎｅｆ含有Ｔ細胞及びその産生方法 |
| JP2022513891A Pending JP2022547837A (ja) | 2019-08-28 | 2020-08-28 | 遺伝子操作されたｔ細胞及びその産生方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513891A Pending JP2022547837A (ja) | 2019-08-28 | 2020-08-28 | 遺伝子操作されたｔ細胞及びその産生方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230085615A2 (https=) |
| EP (2) | EP4022044A4 (https=) |
| JP (2) | JP2022545815A (https=) |
| KR (2) | KR20230004898A (https=) |
| CN (3) | CN119709627A (https=) |
| AU (2) | AU2020336791A1 (https=) |
| CA (2) | CA3152936A1 (https=) |
| IL (1) | IL290946A (https=) |
| MX (1) | MX2022002325A (https=) |
| TW (2) | TW202122574A (https=) |
| WO (2) | WO2021037222A1 (https=) |
| ZA (1) | ZA202202127B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20240226294A9 (en) * | 2021-02-15 | 2024-07-11 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Customized chimeric antigen receptor polypeptides |
| TWI863006B (zh) * | 2021-10-18 | 2024-11-21 | 美商凱特製藥公司 | 用於嵌合抗原受體之信號傳導域 |
| CN120344250A (zh) * | 2022-10-25 | 2025-07-18 | 美商凯维那医疗公司 | 使用抗cd19 car-t细胞疗法治疗狼疮性肾炎的方法 |
| WO2024153211A1 (en) * | 2023-01-19 | 2024-07-25 | Nanjing Legend Biotech Co., Ltd. | Fusion polypeptides for targeted protein degradation and mehtods of use thereof |
| WO2024196969A2 (en) * | 2023-03-20 | 2024-09-26 | Memorial Sloan-Kettering Cancer Center | Cells and compositions for treating cancer |
| CN121419987A (zh) * | 2023-07-07 | 2026-01-27 | 南京传奇生物科技有限公司 | 蛋白质及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070041A2 (en) * | 2004-01-09 | 2005-08-04 | Morehouse School Of Medicine | Modulating vaccine against hiv nef protein-induced lymphocyte depletion |
| WO2018132506A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN108395481B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 |
| BR112019021857A2 (pt) * | 2017-04-19 | 2020-06-02 | Allogene Therapeutics, Inc. | Métodos e composições de célula t aperfeiçoada |
| CN109306014B (zh) * | 2017-07-27 | 2022-04-12 | 上海细胞治疗研究院 | 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途 |
| WO2019126358A1 (en) * | 2017-12-22 | 2019-06-27 | Cell Design Labs, Inc. | Single- and multi-chain chimeric antigen receptors |
| SG11202006050XA (en) * | 2017-12-29 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
| US20210023170A1 (en) * | 2018-02-12 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
-
2020
- 2020-08-28 WO PCT/CN2020/112182 patent/WO2021037222A1/en not_active Ceased
- 2020-08-28 JP JP2022513162A patent/JP2022545815A/ja active Pending
- 2020-08-28 WO PCT/CN2020/112181 patent/WO2021037221A1/en not_active Ceased
- 2020-08-28 JP JP2022513891A patent/JP2022547837A/ja active Pending
- 2020-08-28 CN CN202411536275.7A patent/CN119709627A/zh not_active Withdrawn
- 2020-08-28 KR KR1020227043340A patent/KR20230004898A/ko active Pending
- 2020-08-28 EP EP20856951.7A patent/EP4022044A4/en not_active Withdrawn
- 2020-08-28 EP EP20856772.7A patent/EP4022041A4/en not_active Withdrawn
- 2020-08-28 MX MX2022002325A patent/MX2022002325A/es unknown
- 2020-08-28 KR KR1020227010201A patent/KR20220066291A/ko active Pending
- 2020-08-28 TW TW109129624A patent/TW202122574A/zh unknown
- 2020-08-28 AU AU2020336791A patent/AU2020336791A1/en not_active Abandoned
- 2020-08-28 CN CN202080073506.9A patent/CN114616323B/zh active Active
- 2020-08-28 US US17/639,249 patent/US20230085615A2/en not_active Abandoned
- 2020-08-28 CA CA3152936A patent/CA3152936A1/en active Pending
- 2020-08-28 TW TW109129629A patent/TW202122575A/zh unknown
- 2020-08-28 CA CA3150401A patent/CA3150401A1/en active Pending
- 2020-08-28 US US17/638,738 patent/US20220313738A1/en not_active Abandoned
- 2020-08-28 CN CN202080075654.4A patent/CN114599785A/zh active Pending
- 2020-08-28 AU AU2020339559A patent/AU2020339559A1/en not_active Withdrawn
-
2022
- 2022-02-18 ZA ZA2022/02127A patent/ZA202202127B/en unknown
- 2022-02-27 IL IL290946A patent/IL290946A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP2023080185A (ja) | キメラ抗原受容体 | |
| JP2022113880A5 (https=) | ||
| CN116063550A (zh) | 靶向nk激活性受体的嵌合抗原受体 | |
| Nolan et al. | Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| JP2021532742A5 (https=) | ||
| US11198737B2 (en) | T cell-antigen coupler with Y177 mutation and methods of uses thereof | |
| CN110818802A (zh) | 一种嵌合t细胞受体star及其应用 | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| JP2018535701A5 (https=) | ||
| JPWO2019232444A5 (https=) | ||
| US20100143315A1 (en) | Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof | |
| EP4273175A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JPWO2020228824A5 (https=) | ||
| US20240016841A1 (en) | Cells comprising t cell-antigen couplers and uses thereof | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| JPWO2020228825A5 (https=) | ||
| JPWO2021037221A5 (https=) | ||
| WO2020253879A1 (zh) | 一种双特异性嵌合抗原受体 | |
| JPWO2021037222A5 (https=) | ||
| CN121311239A (zh) | 包含替代信号传导结构域的平行嵌合抗原受体（pCAR）及衔接子嵌合抗原受体及其使用方法 | |
| Marcu-Malina et al. | Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors | |
| KR20260042160A (ko) | 이중특이적 폴리펩티드 분자 | |
| JP2021530238A5 (https=) |